Lumbar Spinal Fibrosis and TNF Alpha Inhibition
Primary Purpose
Post Operative Sciatica by Lumbar Spinal Fibrosis
Status
Completed
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
TNF blocker
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Post Operative Sciatica by Lumbar Spinal Fibrosis focused on measuring Sciatica, Pain, TNF-alpha, Discectomy, Fibrosis, Spine
Eligibility Criteria
Inclusion Criteria:
- age over 18 years old
- sciatica post discectomy
- Pain with VAS > 40 mm and impossibility to have his usual activity
- Surgical discectomy (less than 2 years and more than 6 months)
- Painless of more than one month and less than one year after the discectomy
- MRI with gadolinium injection of less than 6 months and done more than 6 months after the discectomy
- Presence of spinal fibrosis on MRI (hyposignal in T1 enhanced by gadolinium and hypersignal in T2)
- failure of epidural injection treatment
- absence of tuberculosis
- contraception for woman
- informed consent
Exclusion Criteria:
- Chronic psychiatric pathologies not treated
- Presence of conflict between nerve root and herniated disc or disc fragments or spinal stenosis
- severe cognitives troubles
- severe cardiac failure (class III or IV)
- Tuberculosis (active or latent), severe infections
- Cancers
- Allergy reactions to the drug studied
- Difficulties to understand french
- Patients enrolled in another clinical trial in the past three months
- pregnancy, breastfeeding or no contraception
Sites / Locations
- Hopital Cochin
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
TNF-alpha blocker
Placebo
Arm Description
Treatment with TNF-alpha blocker
Treatment with placebo
Outcomes
Primary Outcome Measures
Sciatica pain
Visual analogue scale of lumbar pain
Secondary Outcome Measures
Functional assessments
Full Information
NCT ID
NCT00385086
First Posted
October 4, 2006
Last Updated
October 15, 2015
Sponsor
Assistance Publique - Hôpitaux de Paris
1. Study Identification
Unique Protocol Identification Number
NCT00385086
Brief Title
Lumbar Spinal Fibrosis and TNF Alpha Inhibition
Official Title
Efficacy of TNF-alpha Inhibition in Sciatica With Post-operative Lumbar Spinal Fibrosis
Study Type
Interventional
2. Study Status
Record Verification Date
October 2015
Overall Recruitment Status
Completed
Study Start Date
February 2007 (undefined)
Primary Completion Date
October 2012 (Actual)
Study Completion Date
December 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
TNF-alpha is the main cytokine implicated in the formation of lumbar spinal fibrosis. Inhibiting TNF-alpha could significantly decrease spinal fibrosis after lumbar discectomy.
Detailed Description
OBJECT:
Failed back surgery syndrome is still a challenging therapeutic problem. Clinical studies have demonstrated a significant association between lumbar spinal fibrosis after lumbar discectomy and the recurrence of radicular pain in 25% of cases. Forceful epidural infiltrations, radiotherapy, therapy with D-penicillamine or surgical procedures have had unfavourable results in terms of pain and cost. Magnetic resonance imaging reveals lumbar spinal fibrosis by a hyposignal in the T1 sequence and a hypersignal in T2 sequence around the spinal tissue. Tumor necrosis factor a (TNF-a) is the main cytokine implicated in the formation of tissue fibrosis. In animal models of fibrosis, TNF-a inhibition has been shown to prevent and treat tissue fibrosis.
HYPOTHESIS:
Inhibiting TNF-a could significantly decrease sciatica pain because of lumbar spinal fibrosis after lumbar discectomy by decreasing spinal fibrosis.
METHODS:
We propose a 2-year pilot prospective, randomized, double-blind, controlled study of TNF-a inhibitor (infliximab) in patients with sciatica as a result of postoperative lumbar spinal fibrosis. The infliximab group will receive one intravenous injection of 3 mg/kg infliximab. The control group will receive one physiological serum injection. Patients will be evaluated at day 0, 10, 30, 90, and 180. The main evaluation criterion will be sciatica pain as measured on a visual analog scale, with the objective of a 50% decrease in pain at day 10. This objective leads to a size of 20 patients per group. The other evaluation criteria will be clinical, functional, social, and professional. Patients will be recruited from the rehabilitation unit at Cochin teaching hospital.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post Operative Sciatica by Lumbar Spinal Fibrosis
Keywords
Sciatica, Pain, TNF-alpha, Discectomy, Fibrosis, Spine
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
38 (Actual)
8. Arms, Groups, and Interventions
Arm Title
TNF-alpha blocker
Arm Type
Experimental
Arm Description
Treatment with TNF-alpha blocker
Arm Title
Placebo
Arm Type
Active Comparator
Arm Description
Treatment with placebo
Intervention Type
Drug
Intervention Name(s)
TNF blocker
Intervention Description
Treatment with TNF-alpha blocker
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Treatment with placebo
Primary Outcome Measure Information:
Title
Sciatica pain
Description
Visual analogue scale of lumbar pain
Time Frame
10 days after treatment
Secondary Outcome Measure Information:
Title
Functional assessments
Time Frame
At 10, 30, 90, 180 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age over 18 years old
sciatica post discectomy
Pain with VAS > 40 mm and impossibility to have his usual activity
Surgical discectomy (less than 2 years and more than 6 months)
Painless of more than one month and less than one year after the discectomy
MRI with gadolinium injection of less than 6 months and done more than 6 months after the discectomy
Presence of spinal fibrosis on MRI (hyposignal in T1 enhanced by gadolinium and hypersignal in T2)
failure of epidural injection treatment
absence of tuberculosis
contraception for woman
informed consent
Exclusion Criteria:
Chronic psychiatric pathologies not treated
Presence of conflict between nerve root and herniated disc or disc fragments or spinal stenosis
severe cognitives troubles
severe cardiac failure (class III or IV)
Tuberculosis (active or latent), severe infections
Cancers
Allergy reactions to the drug studied
Difficulties to understand french
Patients enrolled in another clinical trial in the past three months
pregnancy, breastfeeding or no contraception
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Francois Rannou, MD, PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hopital Cochin
City
Paris
ZIP/Postal Code
75014
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
26596627
Citation
Nguyen C, Palazzo C, Grabar S, Feydy A, Sanchez K, Zee N, Quinquis L, Ben Boutieb M, Revel M, Lefevre-Colau MM, Poiraudeau S, Rannou F. Tumor necrosis factor-alpha blockade in recurrent and disabling chronic sciatica associated with post-operative peridural lumbar fibrosis: results of a double-blind, placebo randomized controlled study. Arthritis Res Ther. 2015 Nov 19;17:330. doi: 10.1186/s13075-015-0838-4.
Results Reference
derived
Learn more about this trial
Lumbar Spinal Fibrosis and TNF Alpha Inhibition
We'll reach out to this number within 24 hrs